Last updated: February 14, 2026
Product Overview:
NDC 00603-5063 is identified as Apretude (cabotegravir extended-release injectable suspension), developed by ViiV Healthcare. It is an injectable medication approved for pre-exposure prophylaxis (PrEP) for HIV. Approved by the FDA in December 2021, Apretude offers an alternative to daily oral PrEP with a dosing schedule of once every two months.
Market Context:
The global HIV prevention market is expanding, driven by increased awareness, policy shifts favoring long-acting injectables, and unmet needs among populations with adherence challenges to daily oral regimens. The targeted demographic includes high-risk populations such as men who have sex with men (MSM), transgender women, and intravenous drug users.
Market Size and Penetration:
- The global PrEP market was valued at approximately USD 1.5 billion in 2022.
- The injectable segment is projected to grow at a compound annual growth rate (CAGR) of 15% from 2023 to 2030 ([1]).
- North America dominates with over 70% of market revenues, driven by high HIV prevalence and healthcare infrastructure.
Sales Data and Adoption Rates:
- U.S. prescriptions for cabotegravir injections reached approximately 50,000 in 2022.
- ViiV Healthcare has entered agreements with key payers, favoring the adoption of Apretude.
- Prescriber awareness and patient acceptance are increasing, but barriers include injection logistics, cost, and initial patient education.
Pricing Landscape:
- Apretude's list price for a two-month injection is approximately USD 3,500 to USD 4,000 per dose in the U.S.
- This contrasts with daily oral PrEP (brand Truvada), which costs around USD 18,500 annually, with insurance often reducing out-of-pocket costs.
- The higher price reflects the convenience and longer dosing schedule but may face reimbursement challenges initially.
Competitive Landscape:
- On the market, only GSK's cabotegravir (generic version) and other long-acting injectables are under regulatory review or in clinical trials.
- Traditional daily oral PrEP drugs (e.g., Truvada, Descovy) hold larger market shares but are being gradually replaced in certain sub-segments by injectables.
| Price Projections (Next 5 Years): |
Year |
Expected Average Price per Dose |
Market Penetration |
Notes |
| 2023 |
USD 3,800 |
10% of PrEP market |
Early adoption phase, limited insurance coverage |
| 2024 |
USD 3,700 |
15% |
Price adjusts as competition potentially enters, and insurance coverage expands |
| 2025 |
USD 3,500 |
25% |
Stabilization of pricing, increased prescriber familiarity |
| 2026 |
USD 3,200 |
35% |
Cost reductions from manufacturing efficiencies, broader payer acceptance |
| 2027 |
USD 3,000 |
40% |
Further market penetration, increased volume sales |
Implications:
- The price decline is driven by scaling, competitive pressures, and payer negotiations.
- Insurance coverage and demonstration of long-term cost savings could support sustained or reduced pricing.
Regulatory and Policy Factors:
- Expansion into global markets remains contingent on regulatory approvals in Europe, Asia, and Africa.
- International price negotiations and subsidies may significantly alter projections outside the U.S.
Key Takeaways:
- The uptake of NDC 00603-5063 (Apretude) is projected to grow steadily over the next five years, driven by increased awareness and acceptance of long-acting injectable PrEP.
- Price declines are anticipated to occur as market volume increases, manufacturing scales, and competition emerges.
- Accessibility will depend heavily on insurance coverage, healthcare provider adoption, and regulatory approvals in international markets.
FAQs:
1. What is the current regulatory status of NDC 00603-5063?
FDA approved in December 2021 for PrEP; approved or under review in select international markets.
2. How does the cost of Apretude compare to oral PrEP?
Apretude's list price is approximately USD 3,500–USD 4,000 per two-month dose, significantly higher than the annual USD 18,500 cost of oral Truvada but offers dosing convenience.
3. What factors influence pricing negotiations for Apretude?
Insurance coverage, healthcare provider acceptance, volume discounts, and competitive market entries.
4. What is the expected market share of long-acting injectables by 2027?
Projected to capture around 40% of the global PrEP market, supported by increased demand among populations with adherence challenges.
5. Are there any global market challenges?
Yes. Regulatory delays, reimbursement policies, and manufacturing capacity constraints may impede international market expansion.
Citations:
- MarketWatch, "Global HIV Prevention Market," 2022.
- ViiV Healthcare, product data sheets, 2022.
- IQVIA, Prescription Data, 2022.
